hereditary angioedema

hereditary angioedema
Name	Hereditary angioedema
Field	Immunology, Allergy

hereditary angioedema is a rare genetic disorder characterized by recurrent episodes of severe swelling affecting the skin, mucosa, and internal organs. It presents as episodic, non-pitting, non-pruritic edema that can involve the face, limbs, gastrointestinal tract, and larynx, with potential life-threatening airway compromise. Clinical recognition often relies on family history, physical findings, and specialized laboratory testing performed in tertiary centers affiliated with institutions such as Mayo Clinic, Johns Hopkins Hospital, Massachusetts General Hospital, and national reference laboratories.

Signs and symptoms

Patients typically experience sudden, episodic swelling of the extremities, face, abdomen, or genitals, sometimes accompanied by severe, crampy abdominal pain that can mimic acute surgical conditions treated at hospitals like Mount Sinai Health System and Cleveland Clinic. Laryngeal attacks may present with stridor and can necessitate emergency interventions comparable to those performed in NewYork-Presbyterian Hospital and Guy's and St Thomas' NHS Foundation Trust. Attacks are classically non-urticarial, lacking wheals seen in cases evaluated at centers including Royal Free Hospital and Charité – Universitätsmedizin Berlin. Triggers reported in case series from Stanford Health Care and University of Toronto include trauma, dental procedures performed in clinics like Harvard School of Dental Medicine, hormonal fluctuations linked to care in gynecology departments such as those at Imperial College Healthcare NHS Trust, and emotional stress noted in reports from American Psychological Association conferences.

Pathophysiology

The fundamental defect involves dysregulation of plasma protease systems leading to bradykinin-mediated increased vascular permeability, a mechanism discussed in reviews from Nature Reviews Immunology, The Lancet, and New England Journal of Medicine. Deficiency or dysfunction of C1 inhibitor affects the complement and contact systems studied by researchers at Cold Spring Harbor Laboratory and The Francis Crick Institute. Excess activity of plasma kallikrein and cleavage of high-molecular-weight kininogen increases bradykinin levels, pathways explored in work associated with Max Planck Society and Karolinska Institutet. These molecular events share conceptual links to coagulation factors researched at University of Oxford and University of Cambridge.

Genetics and inheritance

Most classical cases arise from mutations in the SERPING1 gene, first characterized in genetics units at institutions like University of Pennsylvania and University College London. Inheritance is typically autosomal dominant with variable penetrance, a pattern also observed in disorders cataloged by National Institutes of Health and European Society of Human Genetics. Other genetic causes include mutations in FXII, PLG, ANGPT1, and KNG1 reported from consortia involving Broad Institute and Wellcome Trust Sanger Institute. Genetic counseling is provided by services at Genetics Home Reference-linked clinics and programs at Stanford Medicine and UCLA Health.

Diagnosis

Diagnostic evaluation includes measurement of C4 complement levels and quantitative and functional assays of C1 inhibitor performed in reference laboratories affiliated with Centers for Disease Control and Prevention, Molecular Genetics Laboratory at Baylor College of Medicine, and commercial labs used by Mount Sinai Health System. Differential diagnosis may involve ruling out acquired angioedema described in case reports from Mayo Clinic and allergic angioedema managed in emergency departments at Royal Perth Hospital. Imaging such as ultrasound or computed tomography used in abdominal presentations follows protocols from American College of Radiology and clinical guidelines from European Academy of Allergy and Clinical Immunology.

Management and treatment

Acute attacks are managed with therapies targeting bradykinin pathways, including C1 inhibitor concentrates developed in collaboration with companies and centers such as CSL Behring and research from University of Milan. Plasma kallikrein inhibitors and bradykinin B2 receptor antagonists have been studied in randomized trials reported in The Lancet and Journal of Allergy and Clinical Immunology. Long-term prophylaxis may involve attenuated androgens, antifibrinolytics, or newer agents administered under protocols from clinics like Mount Sinai Medical Center and Royal Free Hospital. Emergency airway management follows algorithms practiced in departments at Hospital for Sick Children and Mayo Clinic, and patient education initiatives are supported by patient organizations such as Hereditary Angioedema Association and charitable trusts modeled after National Organization for Rare Disorders.

Epidemiology

Hereditary angioedema has been estimated to affect approximately 1 in 50,000 individuals in studies published by teams at University of Copenhagen and Karolinska Institutet, though prevalence estimates vary across registries maintained by European Network for Rare and Congenital Anaemias and national surveillance programs at Public Health England. Onset often occurs in childhood or adolescence, with variable geographic distribution described in reports from Japan, Brazil, Germany, United States, and Canada. Registries affiliated with Orphanet and multinational cohorts coordinated by groups at Imperial College London contribute to epidemiologic understanding.

History and society

Descriptions of familial angioedema date to clinical observations made by physicians associated with hospitals like St Bartholomew's Hospital and reports compiled in archives of Royal College of Physicians. The biochemical role of C1 inhibitor was elucidated through research at National Institutes of Health and Rockefeller University, and therapeutic developments accelerated with contributions from pharmaceutical companies and academic centers including University of Milan and McGill University. Patient advocacy and awareness efforts mirror campaigns by organizations such as Rare Diseases International and NORD, influencing policy dialogues at bodies like World Health Organization and national health ministries.

Category:Vascular diseases